Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Fexofenadine Hydrochloride
Overview
What is Fexofenadine Hydrochloride?
D
What does Fexofenadine Hydrochloride look like?
What are the available doses of Fexofenadine Hydrochloride?
Sorry No records found.
What should I talk to my health care provider before I take Fexofenadine Hydrochloride?
Sorry No records found
How should I use Fexofenadine Hydrochloride?
Fexofenadine Hydrochloride Tablets are indicated for the relief
of symptoms associated with seasonal allergic rhinitis in adults and children 6
years of age and older. Symptoms treated effectively were sneezing, rhinorrhea,
itchy nose/palate/throat, itchy/watery/red eyes.
Fexofenadine Hydrochloride Tablets are indicated for treatment of
uncomplicated skin manifestations of chronic idiopathic urticaria in adults and
children 6 years of age and older. It significantly reduces pruritus and the
number of wheals.
The recommended dose of Fexofenadine Hydrochloride Tablets is 60
mg twice daily, or 180 mg once daily with water. A dose of 60 mg once daily is
recommended as the starting dose in patients with decreased renal function (see
).
The recommended dose of Fexofenadine Hydrochloride Tablets is 30
mg twice daily with water. A dose of 30 mg once daily is recommended as the
starting dose in pediatric patients with decreased renal function (see ).
The recommended dose of Fexofenadine Hydrochloride Tablets is 60
mg twice daily or 180 mg once daily with water. A dose of 60 mg once daily is
recommended as the starting dose in patients with decreased renal function (see
).
The recommended dose of Fexofenadine Hydrochloride Tablets is 30
mg twice daily with water. A dose of 30 mg once daily is recommended as the
starting dose in pediatric patients with decreased renal function (see ).
What interacts with Fexofenadine Hydrochloride?
Sorry No Records found
What are the warnings of Fexofenadine Hydrochloride?
Sorry No Records found
What are the precautions of Fexofenadine Hydrochloride?
Sorry No Records found
What are the side effects of Fexofenadine Hydrochloride?
Sorry No records found
What should I look out for while using Fexofenadine Hydrochloride?
Fexofenadine Hydrochloride Tablets are contraindicated in
patients with known hypersensitivity to any of its ingredients.
What might happen if I take too much Fexofenadine Hydrochloride?
OVERDOSAGE
How should I store and handle Fexofenadine Hydrochloride?
StorageStore Pantoprazole sodium delayed-release tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]StorageStore Pantoprazole sodium delayed-release tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]Trazodone Hydrochloride Tablets USP, 50 mg are white, film-coated, round, convex, scored tablets, debossed “61” bisect “60” on one side and debossed “V” on the reverse side.Trazodone Hydrochloride Tablets USP, 100 mg are white, film-coated, round, convex, scored tablets, debossed “61” bisect “61” on one side and debossed “V” on the reverse side.Trazodone Hydrochloride Tablets USP, 50 mg are white, film-coated, round, convex, scored tablets, debossed “61” bisect “60” on one side and debossed “V” on the reverse side.Trazodone Hydrochloride Tablets USP, 100 mg are white, film-coated, round, convex, scored tablets, debossed “61” bisect “61” on one side and debossed “V” on the reverse side.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Fexofenadine hydrochloride, the major active metabolite of
terfenadine, is an antihistamine with selective peripheral H-receptor antagonist activity. Both enantiomers of
fexofenadine hydrochloride displayed approximately equipotent antihistaminic
effects. Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in
sensitized guinea pigs and histamine release from peritoneal mast cells in rats.
The clinical significance of these findings is unknown. In laboratory animals,
no anticholinergic or alpha-adrenergic blocking effects
were observed. Moreover, no sedative or other central nervous system effects
were observed. Radiolabeled tissue distribution studies in rats indicated that
fexofenadine does not cross the blood-brain barrier.
Non-Clinical Toxicology
Fexofenadine Hydrochloride Tablets are contraindicated in patients with known hypersensitivity to any of its ingredients.In vitro
Carbamazepine reduced plasma concentrations of trazodone when co-administered. Patients should be closely monitored to see if there is a need for an increased dose of trazodone when taking both drugs.
Increased serum digoxin or phenytoin levels have been reported to occur in patients receiving trazodone concurrently with either of those two drugs.
It is not known whether interactions will occur between monoamine oxidase (MAO) inhibitors and trazodone. Due to the absence of clinical experience, if MAO inhibitors are discontinued shortly before or are to be given concomitantly with trazodone, therapy should be initiated cautiously with gradual increase in dosage until optimum response is achieved.
PRECAUTIONS Information for Patients Patients taking Fexofenadine Hydrochloride Tablets should receive the following information: Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism. However, co-administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine. Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study). No differences in adverse events or QT interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole. The findings of these studies are summarized in the following table: Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox) decreased fexofenadine AUC by 41% and Cmax by 43%. Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. Interactions with Fruit Juices Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine. This is based on the results from 3 clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis. The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water. Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice. The clinical significance of these observations is unknown. In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%. Therefore, to maximize the effects of fexofenadine, it is recommended that Fexofenadine hydrochloride should be taken with water (see ). CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY Teratogenic Effects Nonteratogenic EffectsNURSING MOTHERS It is not known if fexofenadine is excreted in human milk. There are no adequate and well-controlled studies in women during lactation. Because many drugs are excreted in human milk, caution should be exercised when fexofenadine hydrochloride is administered to a nursing woman. PEDIATRIC USE GERIATRIC USE Clinical studies of fexofenadine hydrochloride tablets and capsules did not include sufficient numbers of subjects aged 65 years and over to determine whether this population responds differently from younger subjects. Other reported clinical experience has not identified differences in responses between the geriatric and younger subjects. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See ).
ADVERSE REACTIONS Seasonal Allergic Rhinitis Adults Pediatrics Three clinical safety studies in 845 children aged 6 months to 5 years comparing 15 mg twice daily (n=85) and 30 mg twice daily (n=330) of an experimental formulation of fexofenadine to placebo (n=430) have been conducted. In general, fexofenadine hydrochloride was well tolerated in these studies. No unexpected adverse events were seen given the known safety profile of fexofenadine and likely adverse reactions for this patient population. (See .) Chronic Idiopathic Urticaria Adverse events reported by subjects 12 years of age and older in placebo-controlled chronic idiopathic urticaria studies were similar to those reported in placebo-controlled seasonal allergic rhinitis studies. In placebo-controlled chronic idiopathic urticaria clinical trials, which included 726 subjects 12 years of age and older receiving fexofenadine hydrochloride tablets at doses of 20 to 240 mg twice daily, adverse events were similar in fexofenadine hydrochloride- and placebo-treated patients. Table 3 lists adverse experiences in subjects aged 12 years and older which were reported by greater than 2% of subjects treated with fexofenadine hydrochloride 60 mg tablets twice daily in controlled clinical studies in the United States and Canada and that were more common with fexofenadine hydrochloride than placebo. In a placebo-controlled clinical study in the United States, which included 167 subjects aged 12 years and older receiving fexofenadine hydrochloride 180 mg tablets, adverse events were similar in fexofenadine hydrochloride- and placebo-treated subjects. Table 3 also lists adverse experiences that were reported by greater than 2% of subjects treated with fexofenadine hydrochloride tablets at doses of 180 mg once daily and that were more common with fexofenadine hydrochloride than placebo.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
515Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).